10-Q · May 8, 2026
Matinas BioPharma Holdings, Inc. reported a net loss of $1,921 for Q1 2026, an increase from a loss of $1,656 in Q1 2025, indicating continued financial struggles. Research and development expenditures dropped…
Earnings analysis · 10-Q
MTNB earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied filing extract does not include income-statement, balance-sheet, cash-flow, or segment tables; the reported earnings data shows Q2 EPS of -$0.21 and revenue of $0.0. The dominant developments are the…
Read full summary
The supplied filing extract does not include income-statement, balance-sheet, cash-flow, or segment tables; the reported earnings data shows Q2 EPS of -$0.21 and revenue of $0.0. The dominant developments are the additional NYSE American noncompliance notice based on $3,022 of stockholders’ equity versus the $4,000 requirement and the October 2, 2027 compliance deadline. The proposed transactions may provide a strategic path forward, but failure to close could require substantial additional funding or a winddown, while existing stockholders are expected to retain approximately 9% ownership after completion.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.21
What stood out
-
Lease Dispute Resolved
The company resolved its Bridgewater landlord litigation through a settlement effective April 7, 2026, making a $765 termination payment and exiting the premises on April 29, 2026.
-
Disclosure Controls Effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, with no material changes to internal control over financial reporting during Q2 2026.
-
Strategic Transactions Announced
Matinas entered into a Business Combination Agreement and Stock Purchase Agreement on July 10, 2026, providing potential strategic alternatives while the company seeks to address its capital and listing challenges.
What to watch
-
NYSE American Delisting Risk
NYSE American issued an additional June 24, 2026 notice citing stockholders’ equity of $3,022 as of March 31, 2026, below the $4,000 requirement under Section 1003(a)(ii). The company has until October 2, 2027 to regain compliance, but failure could lead to delisting.
-
Transaction Execution Risk
The proposed Business Combination and Stock Sale are subject to shareholder approval and other closing conditions. The Business Combination Agreement may require a $1.0 million termination fee in specified circumstances if the transaction does not close.
-
Funding and Dilution Risk
If the Business Combination and Stock Sale are not completed, the company states it would need substantial additional funding and its board may pursue a winddown, dissolution or liquidation. Current stockholders are expected to own approximately 9% of Pubco Common Shares after the Business Combination, subject to adjustment.
Management's outlook
No quantitative revenue or EPS guidance was provided in the supplied 10-Q extract. Management states that the NYSE American granted a plan period through October 2, 2027 to regain compliance, but no operating outlook was disclosed.
Earlier filings 4
10-K · March 31, 2026
Matinas (MTNB) is a clinical-stage biotech focused on an oral amphotericin B candidate, MAT2203, built on its LNC delivery platform. The 10-K emphasizes strong Phase 2 signals (EFA and survival) and an FDA-agreed Phase…
10-Q · November 10, 2025
Matinas reported a smaller quarterly loss with net loss per share of $(0.40) for the three months ended September 30, 2025 versus $(0.85) in the year-ago quarter, driven by sharply lower R&D and overall operating…
10-Q · August 14, 2025
Matinas reported no revenue for Q2 and a net loss of $5,245 (reported as $(5,245) in the filing) for the three months ended June 30, 2025, or $(1.03) per share, improving from $(5,719) and $(1.15) in the prior-year…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.